RECRUITING

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Talk to us

Conditions

Chronic Graft Versus Host Disease

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial collects clinical data and blood samples to predict the quality of response to specific treatments in patients with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy. Collecting and analyzing clinical data and blood samples from patients with cGVHD before and after treatment initiation may help doctors identify changes that may predict treatment response.

Official Title

Predicting the Quality of Response to Specific Treatments (PQRST)

Quick Facts

Study Start:2020-06-29
Study Completion:2026-08-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04431479

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults age 18 or older
  2. * Prior allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
  3. * No evidence of persistent or progressive malignancy at the time of enrollment
  4. * Agrees to be evaluated at the transplant center before a new line of treatment is started (may be concurrent with the enrollment visit), and later between 2-6 weeks, 3 months and 6 months after index treatment is started or if an additional new therapy is started before 6 months
  5. * Signed, informed consent
  1. * Inability to comply with study procedures
  2. * Uncontrolled psychiatric disorder
  3. * Anticipated survival \< 6 months

Contacts and Locations

Study Contact

Gaby Desatnik
CONTACT
206-667-1356
cgvhd@fredhutch.org

Principal Investigator

Stephanie J. Lee
PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium

Study Locations (Sites)

University of Florida
Gainesville, Florida, 32610
United States
Moffitt Cancer Center
Tampa, Florida, 33612
United States
Dana-Farber Harvard Cancer Center
Boston, Massachusetts, 02115
United States
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455
United States
Roswell Park Cancer Institute
Buffalo, New York, 14263
United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232
United States
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232
United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: Fred Hutchinson Cancer Center

  • Stephanie J. Lee, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-06-29
Study Completion Date2026-08-02

Study Record Updates

Study Start Date2020-06-29
Study Completion Date2026-08-02

Terms related to this study

Additional Relevant MeSH Terms

  • Chronic Graft Versus Host Disease